These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

588 related items for PubMed ID: 16964191

  • 1. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
    Marberger M.
    Nat Clin Pract Urol; 2006 Sep; 3(9):495-503. PubMed ID: 16964191
    [Abstract] [Full Text] [Related]

  • 2. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ, Miner M.
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [Abstract] [Full Text] [Related]

  • 3. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
    Naslund M, Eaddy MT, Hogue SL, Kruep EJ, Shah MB.
    Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
    [Abstract] [Full Text] [Related]

  • 4. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
    Emberton M, Zinner N, Michel MC, Gittelman M, Chung MK, Madersbacher S.
    BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135
    [Abstract] [Full Text] [Related]

  • 5. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG.
    BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
    [Abstract] [Full Text] [Related]

  • 6. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.
    Siami P, Roehrborn CG, Barkin J, Damiao R, Wyczolkowski M, Duggan A, Major-Walker K, Morrill BB, CombAT study group.
    Contemp Clin Trials; 2007 Nov; 28(6):770-9. PubMed ID: 17761460
    [Abstract] [Full Text] [Related]

  • 7. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
    Montorsi F, Alcaraz A, Desgrandchamps F, Hammerer P, Schröder F, Castro R.
    Prostate; 2009 Jun 01; 69(8):895-907. PubMed ID: 19267353
    [Abstract] [Full Text] [Related]

  • 8. 5alpha-reductase inhibition for men with enlarged prostate.
    Issa MM, Kraft KH.
    J Am Acad Nurse Pract; 2007 Aug 01; 19(8):398-407. PubMed ID: 17655569
    [Abstract] [Full Text] [Related]

  • 9. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
    Rittmaster RS.
    Best Pract Res Clin Endocrinol Metab; 2008 Apr 01; 22(2):389-402. PubMed ID: 18471794
    [Abstract] [Full Text] [Related]

  • 10. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA, McVary KT.
    Int J Impot Res; 2008 Dec 01; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [Abstract] [Full Text] [Related]

  • 11. An overview on 5alpha-reductase inhibitors.
    Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M.
    Steroids; 2010 Feb 01; 75(2):109-53. PubMed ID: 19879888
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
    Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C, ARIA3001, ARIA3002 and ARIB3003 Study Investigators.
    Eur Urol; 2004 Oct 01; 46(4):488-94; discussion 495. PubMed ID: 15363566
    [Abstract] [Full Text] [Related]

  • 13. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002).
    Vela-Navarrete R, Gonzalez-Enguita C, Garcia-Cardoso JV, Manzarbeitia F, Sarasa-Corral JL, Granizo JJ.
    BJU Int; 2005 Nov 01; 96(7):1045-8. PubMed ID: 16225526
    [Abstract] [Full Text] [Related]

  • 14. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression.
    Trachtenberg J.
    BJU Int; 2005 Jun 01; 95 Suppl 4():6-11. PubMed ID: 15871730
    [Abstract] [Full Text] [Related]

  • 15. [Drug therapy for benign prostatic syndrome (BPS)].
    Berges R.
    Aktuelle Urol; 2006 Sep 01; 37(5):351-62. PubMed ID: 17004180
    [Abstract] [Full Text] [Related]

  • 16. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
    Roehrborn CG.
    BJU Int; 2006 Apr 01; 97(4):734-41. PubMed ID: 16536764
    [Abstract] [Full Text] [Related]

  • 17. [Benign prostatic hyperplasia: medical therapy].
    Schlenker B, Gratzke C, Weidlich P, Seitz M, Reich O, Stief CG.
    MMW Fortschr Med; 2007 Aug 16; 149(33-34):29-31; quiz 32. PubMed ID: 17912863
    [Abstract] [Full Text] [Related]

  • 18. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
    McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA, Medical Therapy of Prostatic Symptoms (MTOPS) Research Group.
    N Engl J Med; 2003 Dec 18; 349(25):2387-98. PubMed ID: 14681504
    [Abstract] [Full Text] [Related]

  • 19. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery.
    Boyle P, Roehrborn C, Harkaway R, Logie J, de la Rosette J, Emberton M.
    Eur Urol; 2004 May 18; 45(5):620-6; discussion 626-7. PubMed ID: 15082205
    [Abstract] [Full Text] [Related]

  • 20. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
    Pinto F, Racioppi M, Sacco E, Totaro A, Brescia A, Volpe A, Gardi M, Bassi PF.
    Arch Ital Urol Androl; 2009 Mar 18; 81(1):1-8. PubMed ID: 19499750
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.